IBRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
48.8M
-4.7%
51.2M
+15.9%
44.2M
+15.5%
38.3M
+19.4%
32.1M
Cost of Revenue
1.3M
+333.2%
298.0K
+25.2%
238.0K
-37.7%
382.0K
+115.8%
177.0K
Gross Profit
47.5M
-6.7%
50.9M
+15.9%
44.0M
+16.0%
37.9M
+18.9%
31.9M
Operating Expenses
125.5M
+11.5%
112.6M
-1.0%
113.8M
+10.9%
102.6M
+17.2%
87.5M
R&D
71.5M
+17.6%
60.8M
-10.6%
68.0M
+6.5%
63.9M
+24.6%
51.2M
SG&A
54.0M
+4.2%
51.8M
+13.2%
45.8M
+18.2%
38.7M
+6.7%
36.3M
Operating Income
-77987000
-26.4%
-61697000
+11.6%
-69791000
-7.9%
-64683000
-16.3%
-55630000
EBITDA
-74098000
-29.3%
-57290000
+12.4%
-65411000
-7.6%
-60818000
-17.7%
-51679000
Net Income
-184565000
+19.9%
-230390000
+63.6%
-632797000
-921.3%
-61958000
+7.9%
-67274000
EPS (Basic)
$-0.17
+22.7%
$-0.22
+64.5%
$-0.62
-933.3%
$-0.06
+14.3%
$-0.07
EPS (Diluted)
$-0.18
+18.2%
$-0.22
+64.5%
$-0.62
-933.3%
$-0.06
+14.3%
$-0.07
Shares (Diluted)
1.1B
+1.0%
1.1B
+2.3%
1.0B
+3.6%
991.5M
+4.7%
946.6M
ImmunityBio (IBRX) — Financials